VRAY - ViewRay, Inc.
| Previous Close | 6.04 |
| Open | 6.00 |
| Bid | 5.90 x 4000 |
| Ask | 6.50 x 800 |
| Day's Range | 5.98 - 6.30 |
| 52 Week Range | 5.80 - 13.21 |
| Volume | 931,314 |
| Avg. Volume | 1,406,785 |
| Market Cap | 602.143M |
| Beta (3Y Monthly) | 1.81 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.18 |
| Earnings Date | Nov 13, 2017 - Nov 17, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.72 |
- Insider Monkey•4 days ago
Is ViewRay, Inc. (VRAY) A Good Stock To Buy?
“Value has performed relatively poorly since the 2017 shift, but we believe challenges to the S&P 500’s dominance are mounting and resulting active opportunities away from the index are growing. At some point, this fault line will break, likely on the back of rising rates, and all investors will be reminded that the best time […]
- PR Newswire•7 days ago
ViewRay® to Present at the 37th Annual J.P. Morgan Healthcare Conference
CLEVELAND , Dec. 10, 2018 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the Company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California . ...
- Motley Fool•9 days ago
Why ViewRay Stock Lost 22% in November
Investors weren't happy with the radiation therapy specialist's latest earnings results.
- GlobeNewswire•14 days ago
Report: Exploring Fundamental Drivers Behind Wayfair, TEGNA, Genpact, ViewRay, United States Steel, and Windstream — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•26 days ago
Rob Fuchs joins ViewRay as Chief Human Resources Officer
CLEVELAND , Nov. 21, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the world's first and only clinical MRI-guided radiation therapy system, announced today the appointment of Robert M. Fuchs ...
- Thomson Reuters StreetEvents•26 days ago
Edited Transcript of VRAY earnings conference call or presentation 8-Nov-18 9:30pm GMT
Q3 2018 ViewRay Inc Earnings Call
- PR Newswire•last month
ViewRay® to Present at 30th Annual Piper Jaffray Healthcare Conference
CLEVELAND , Nov. 14, 2018 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that company management is scheduled to participate in a fireside chat at the 30 th Annual Piper Jaffray Healthcare ...
- GuruFocus.com•last month
Viewray Inc (VRAY) President & CEO Scott William Drake Bought $388,200 of Shares
President & CEO of Viewray Inc (NASDAQ:VRAY) Scott William Drake bought 60,000 shares of VRAY on 11/13/2018 at an average price of $6.47 a share.
- Motley Fool•last month
Why ViewRay Inc. Is Sinking Today
Shares plunge after the company reports third-quarter results that missed the mark and lowers guidance. Is something wrong with the business?
- Associated Press•last month
ViewRay: 3Q Earnings Snapshot
The Oakwood Village, Ohio-based company said it had a loss of 39 cents per share. Losses, adjusted for non-recurring costs and severance costs, came to 25 cents per share. The results missed Wall Street ...
- PR Newswire•last month
ViewRay Reports Third Quarter 2018 Results
CLEVELAND , Nov. 8, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) ("the Company") today announced financial results for the third quarter ended September 30, 2018 . Third Quarter 2018 Highlights: ...
- PR Newswire•2 months ago
ViewRay signs agreement with GenesisCare to bring the first MRIdian MRI-guided radiotherapy systems to the UK
CLEVELAND, Oct. 29, 2018 /PRNewswire/ -- ViewRay, Inc. (VRAY) today announced a collaboration with GenesisCare, the largest provider of cancer services in the UK, Spain and Australia, to introduce the first MRIdian MRI-guided radiotherapy system in the UK to benefit cancer patients.
- GlobeNewswire•2 months ago
Report: Developing Opportunities within Vitamin Shoppe, Intercept Pharmaceuticals, Viasat, Team, Valvoline, and ViewRay — Future Expectations, Projections Moving into 2018
NEW YORK, Oct. 24, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•2 months ago
Real-Time Adaptive Radiotherapy Capabilities of ViewRay's MRIdian Highlighted at Investor & Analyst Meeting at ASTRO 2018
The meeting featured presentations highlighting clinical experiences with the MRIdian System from leading radiation oncologists at the Moffitt Cancer Center and David Geffen School of Medicine at UCLA. A presentation by Louis B. Harrison, M.D., FASTRO, Chair and Senior Member, Department of Radiation Oncology at Moffitt Cancer Center, highlighted the opportunity for MRI-guided radiotherapy in the treatment of cancer and its potential contribution to personalizing radiation therapy including emerging areas of interest such as optimization of treatment through an adaptive therapy loop and diffusion weighted imaging to predict tumor response.
- PR Newswire•2 months ago
ViewRay Announces Conference Call and Webcast of Third Quarter 2018 Financial Results to be Held After Market on November 8, 2018
CLEVELAND , Oct. 18, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its third quarter 2018 financial results, which will take place after the market ...
- PR Newswire•2 months ago
ASTRO 2018 Presentations to Feature Unique Capabilities and Clinical Outcomes of ViewRay's MRIdian Next Generation Cancer Care
Presentations to Highlight Clinical Value of World's Only FDA-Cleared MRI-guided Radiotherapy System CLEVELAND , Oct. 16, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's ...
- PR Newswire•2 months ago
ViewRay® to Host Investor & Analyst Meeting at 2018 ASTRO Annual Meeting in San Antonio
Leading Oncologists to Highlight MRIdian MRI-Guided Adaptive Radiotherapy, Discuss Emergence as a New Potential Standard of Cancer Care CLEVELAND , Oct. 9, 2018 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) ...
- Simply Wall St.•2 months ago
What does ViewRay Inc’s (NASDAQ:VRAY) Balance Sheet Tell Us About Its Future?
Investors are always looking for growth in small-cap stocks like ViewRay Inc (NASDAQ:VRAY), with a market cap of US$890m. However, an important fact which most ignore is: how financially healthy Read More...
- PR Newswire•2 months ago
ViewRay Appoints Industry Veteran James Alecxih as Chief Commercial Officer
CLEVELAND, Oct. 2, 2018 /PRNewswire/ -- ViewRay, Inc. (VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the appointment of James "Jim" Alecxih as Chief Commercial Officer, effective September 17th, 2018. Mr. Alecxih joins the ViewRay leadership team with extensive experience in commercializing new and innovative devices globally and will be responsible for driving the Company's commercial expansion. Prior to joining ViewRay, Mr. Alecxih served as Vice President of Worldwide Sales at Nevro, where he led the high-growth neuromodulation device company's commercial efforts across multiple geographies. Mr. Alecxih also spent 14 years at Intuitive Surgical, where he served most recently as Senior Vice President of Sales for North America, South America, Australia and New Zealand.
- PR Newswire•3 months ago
MRI-Guided Radiation Therapy Aims to Prolong Survival and Reduce Complications for the Most Challenging Cancers
CLEVELAND, Oct. 1, 2018 /PRNewswire/ -- Leading oncology experts from around the world met to discuss the integration of magnetic resonance imaging (MRI) with radiation therapy and its potential to extend life expectancy and reduce common side effects in many cancer patients. ViewRay, Inc. (VRAY), maker of MRIdian®, the world's first and only FDA-cleared, MRI-guided radiation therapy system, and Miami Cancer Institute, co-hosted experts from research hospitals at the cutting-edge of cancer treatment at the September 28 symposium and panel discussion.
Market Realist•3 months agoExploring ViewRay’s Operational Performance
ViewRay (VRAY) incurred general and administrative expenses of $10.5 million in the second quarter compared to $7.46 million in the second quarter of 2017. Its selling and marketing expenses increased from $1.87 million in the second quarter of 2017 to $3.39 million in the second quarter of 2018 due to an increase in its head count to support its growing sales efforts.
Market Realist•3 months agoWhat ViewRay’s Valuation Trend Indicates
In September, of the seven analysts covering ViewRay (VRAY), six have given its stock “buy” or higher ratings, and one analyst has given it a “sell” rating. The mean rating for ViewRay stock is a 2, and its target price is $12.71, implying an upside potential of 30.8% over its closing price of $9.72 on September 27. In comparison, for peers Intuitive Surgical (ISRG), Medtronic (MDT), and Zimmer Biomet Holdings (ZBH), analysts have mean ratings of 2.06, 2.24, and 2.25, respectively, and target prices of $565.8, $102.45, and $136.39, respectively.
Market Realist•3 months agoWhat to Expect from ViewRay in 2018 and Beyond
ViewRay (VRAY) designs, manufactures, and commercializes the MR (magnetic resonance) image-guided radiation therapy system MRIdian. MRIdian combines MRI (magnetic resonance imaging) and external beam radiation therapy and is used to image and treat cancer patients simultaneously. ViewRay entered into a distribution agreement with Itochu to sell MRIdian products in Japan for a consideration of $4.0 million.
- PR Newswire•3 months ago
ViewRay® to Present at the 2018 Cantor Global Healthcare Conference
CLEVELAND , Sept. 25, 2018 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that members of the executive management team are scheduled to present at the Cantor Global Healthcare Conference ...
- PR Newswire•3 months ago
ViewRay Announces Equity Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND , Sept. 17, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today ...
